GlassScriptPhysician profile
Jack C Feng
NPI 1710964481
$17,008.76
in general payments reported to CMS, 2019-2025
42 companies · $3,991 in 2025
The $3,991 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,842 · 2020: $506 · 2021: $166 · 2022: $3,024 · 2023: $3,693 · 2024: $3,786 · 2025: $3,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,359.00 |
| Education | $111.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,604.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,553.67 | 2020-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,427.37 | 2019-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $1,119.37 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $954.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $751.70 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $610.95 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $492.88 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $490.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $488.81 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $361.72 | 2023-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $267.01 | 2020-2023 | Simponi, Tremfya |
| Braintree Laboratories, INC. | $250.11 | 2019-2025 | Suflave, Sutab |
| Pfizer INC. | $249.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $243.16 | 2022-2023 | Zeposia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $239.12 | 2024-2025 | Ibsrela |
| Erbe USA INC | $188.12 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $178.28 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $171.92 | 2019-2025 | |
| Vivus LLC | $155.55 | 2019-2025 | Qsymia, Pancreaze |
| Covidien LP | $142.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $106.15 | 2022-2025 | Rebyota, Clenpiq |
| Allergan, INC. | $105.21 | 2019-2020 | |
| Lilly USA, LLC | $97.12 | 2024-2025 | Omvoh |
| Capsovision, INC. | $88.91 | 2025 | Capsocam Plus |
| Redhill Biopharma INC. | $73.77 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Merck Sharp & Dohme LLC | $69.73 | 2019-2020 | |
| Medtronic, INC. | $65.88 | 2022-2024 | Nexpowder, Gi Genius |
| Daiichi Sankyo INC. | $55.22 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $50.60 | 2022-2023 | Linzess |
| Exact Sciences Corporation | $48.35 | 2023-2025 | Cologuard Collection Kit |
| Celltrion USA INC. | $47.12 | 2024-2025 | Vegzelma, Zymfentra |
| Alfasigma USA, INC. | $43.91 | 2022 | |
| Fresenius Kabi USA, LLC | $32.87 | 2023 | |
| Shionogi INC | $31.60 | 2019 | |
| Astellas Pharma US INC | $27.97 | 2025 | Vyloy |
| Biocon Biologics INC | $27.34 | 2025 | Hulio |
| Alcresta Therapeutics, INC. | $22.04 | 2024 | Relizorb |
| Axonics, INC. | $21.42 | 2022 | |
| W. L. Gore & Associates, INC. | $19.07 | 2020 | |
| Albireo Pharma, INC. | $17.89 | 2024 | Iqirvo |
| Boston Scientific Corporation | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.